BL PharmTech Corp
KOSDAQ:065170
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BL PharmTech Corp
Net Income (Common)
BL PharmTech Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BL PharmTech Corp
KOSDAQ:065170
|
Net Income (Common)
-₩6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-12%
|
|
|
AmorePacific Corp
KRX:090430
|
Net Income (Common)
₩235.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
46%
|
CAGR 10-Years
-9%
|
|
|
Amorepacific Group
KRX:002790
|
Net Income (Common)
₩112.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
79%
|
CAGR 10-Years
-8%
|
|
|
Cosmax Inc
KRX:192820
|
Net Income (Common)
₩123.1B
|
CAGR 3-Years
81%
|
CAGR 5-Years
42%
|
CAGR 10-Years
19%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Net Income (Common)
-₩100.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Net Income (Common)
₩125.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
BL PharmTech Corp
Glance View
BL Pharmtech Corp. engages in health food industry. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2002-11-19. The firm operates its business through four segments. The Health Functional Food Business segment is engaged in the manufacture and sale of products such as red ginsengs, diet foods and vitamins. The Cosmetics Business segment is engaged in the manufacture and sale of anti-aging skincare products and, among others. The Diagnostic and Medical Business segment is engaged in the manufacture and sale of diagnostic kits and other products. The Other segment is engaged in the distribution of health foods and other products.
See Also
What is BL PharmTech Corp's Net Income (Common)?
Net Income (Common)
-6B
KRW
Based on the financial report for Sep 30, 2025, BL PharmTech Corp's Net Income (Common) amounts to -6B KRW.
What is BL PharmTech Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-12%
Over the last year, the Net Income (Common) growth was -116%. The average annual Net Income (Common) growth rates for BL PharmTech Corp have been 21% over the past three years , 15% over the past five years , and -12% over the past ten years .
